Home›Trial›NCT06636071
🔬NCT06636071Phase 3ACTIVE NOT RECRUITING

Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta

Study Summary

The primary objective of the study is to evaluate the effect of setrusumab on reduction in fracture rate, including morphometric vertebral fractures.

Conditions
Osteogenesis Imperfecta
Interventions / Drugs
setrusumab
View on ClinicalTrials.gov ↗
Sponsor
RARE
Ultragenyx Pharmaceutical
Rare Disease
C63/100
Study Details
Enrollment6 participants
Primary Completion—
Lead SponsorUltragenyx Pharmaceutical Inc
Data Retrieved2026-04-11 04:25:35.045806+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.